View Item 

Show simple item record

Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia
dc.contributor.authorKunju, Lakshmi P.en_US
dc.contributor.authorLee, Cheryl T.en_US
dc.contributor.authorMontie, James E.en_US
dc.contributor.authorShah, Rajal B.en_US
dc.date.accessioned2010-06-01T21:44:24Z
dc.date.available2010-06-01T21:44:24Z
dc.date.issued2005-05en_US
dc.identifier.citationKunju, Lakshmi P.; Lee, Cheryl T.; Montie, James; Shah, Rajal B. (2005). "Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia." Pathology International 55(5): 248-254. <http://hdl.handle.net/2027.42/74783>en_US
dc.identifier.issn1320-5463en_US
dc.identifier.issn1440-1827en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74783
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15871722&dopt=citationen_US
dc.format.extent747926 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ptyen_US
dc.rights2005 Blackwell Publishing Ltden_US
dc.subject.otherCarcinoma in Situen_US
dc.subject.otherCytokeratin 20en_US
dc.subject.otherImmunohistochemistryen_US
dc.subject.otherKi-67en_US
dc.subject.otherUrinary Bladderen_US
dc.subject.otherUrothelial Dysplasiaen_US
dc.titleUtility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasiaen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPathologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUrology, University of Michigan School of Medicine, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationotherPathology anden_US
dc.identifier.pmid15871722en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74783/1/j.1440-1827.2005.01821.x.pdf
dc.identifier.doi10.1111/j.1440-1827.2005.01821.xen_US
dc.identifier.sourcePathology Internationalen_US
dc.identifier.citedreferenceEble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.en_US
dc.identifier.citedreferenceEpstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435 – 48.en_US
dc.identifier.citedreferenceCheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999; 23: 443 – 7.en_US
dc.identifier.citedreferenceCheng L, Cheville JC, Neumann RM et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999; 85: 2469 – 74.en_US
dc.identifier.citedreferenceHarnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996; 78: 870 – 75.en_US
dc.identifier.citedreferenceMcKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol 2001; 25: 1074 – 8.en_US
dc.identifier.citedreferenceSun W, Zhang PL, Herrera GA. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder. Appl Immunohistochem Mol Morphol 2002; 10: 327 – 31.en_US
dc.identifier.citedreferenceMallofre C, Castillo M, Morente V, Sole M. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol 2003; 16: 187 – 91.en_US
dc.identifier.citedreferenceRetz M, Lehmann J, Amann E, Wullich B, Roder C, Stockle M. Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor. J Urol 2003; 169: 86 – 9.en_US
dc.identifier.citedreferenceByrne RR, Shariat SF, Brown R et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001; 165: 1473 – 9.en_US
dc.identifier.citedreferenceShariat SF, Pahlavan S, Baseman AG et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology 2001; 57: 60 – 65.en_US
dc.identifier.citedreferenceSun W, Herrera GA. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma. Hum Pathol 2002; 33: 996 – 1000.en_US
dc.identifier.citedreferenceMazerolles C, Rishmann P, Chopin D et al. Usefulness of MIB1 monoclonal antibody in assessing the proliferative index in human bladder carcinoma: comparison with Ki-67 antibody. Histopathology 1994; 25: 563 – 8.en_US
dc.identifier.citedreferenceBringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993; 53: 3241 – 5.en_US
dc.identifier.citedreferenceKim JC, Steinberg GD. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. J Urol 2001; 165: 745 – 56.en_US
dc.identifier.citedreferenceGenega EM, Hutchinson B, Reuter VE, Gaudin PB. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol 2000; 13: 1186 – 91.en_US
dc.identifier.citedreferenceParker DC, Folpe AL, Bell J et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol 2003; 27: 1 – 10.en_US
dc.identifier.citedreferenceSu JS, Arima K, Hasegawa M et al. [Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.] Hinyokika Kiyo 2003; 49: 649 – 58 (in Japanese).en_US
dc.identifier.citedreferenceLipponen PK, Eskelinen MJ, Nordling S. Progression and survival in transitional cell bladder cancer: a comparison of established prognostic factors, S-phase fraction and DNA ploidy. Eur J Cancer 1991; 27: 877 – 81.en_US
dc.identifier.citedreferenceKilicli-Camur N, Kilicaslan I, Gulluoglu MG, Esen T, Uysal V. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int 2002; 52: 463 – 9.en_US
dc.identifier.citedreferenceTsujihashi H, Nakanishi A, Matsuda H, Uejima S, Kurita T. Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining. J Urol 1991; 145: 846 – 9.en_US
dc.identifier.citedreferenceCina SJ, Lancaster-Weiss KJ, Lecksell K, Epstein JI. Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Arch Pathol Lab Med 2001; 125: 646 – 51.en_US
dc.identifier.citedreferenceWakatsuki S, Watanabe R, Saito K et al. Loss of human E-cadherin (ECD) correlated with invasiveness of transitional cell cancer in the renal pelvis, ureter and urinary bladder. Cancer Lett 1996; 103: 11 – 17.en_US
dc.identifier.citedreferenceSyrigos KN, Harrington K, Waxman J, Krausz T, Pignatelli M. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J Urol 1998; 160: 1889 – 93.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1440-1827.2005.01821.x.pdf
Size:
730.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.